ADC Therapeutics Competitors

TG Therapeutics (NASDAQ:TGTX) and ADC Therapeutics (NYSE:ADCT) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, dividends, risk, profitability and institutional ownership.

Analyst Ratings

This is a summary of recent recommendations for TG Therapeutics and ADC Therapeutics, as reported by MarketBeat.com.

TG Therapeutics currently has a consensus price target of $64.00, suggesting a potential upside of 39.37%. ADC Therapeutics has a consensus price target of $47.50, suggesting a potential upside of 104.65%. Given ADC Therapeutics' higher probable upside, analysts plainly believe ADC Therapeutics is more favorable than TG Therapeutics.

Profitability

This table compares TG Therapeutics and ADC Therapeutics' net margins, return on equity and return on assets.

Earnings & Valuation

This table compares TG Therapeutics and ADC Therapeutics' revenue, earnings per share (EPS) and valuation.

ADC Therapeutics has higher revenue and earnings than TG Therapeutics. TG Therapeutics is trading at a lower price-to-earnings ratio than ADC Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

65.7% of TG Therapeutics shares are owned by institutional investors. Comparatively, 40.9% of ADC Therapeutics shares are owned by institutional investors. 13.2% of TG Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

ADC Therapeutics beats TG Therapeutics on 7 of the 13 factors compared between the two stocks.

Ionis Pharmaceuticals (NASDAQ:IONS) and ADC Therapeutics (NYSE:ADCT) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, valuation, earnings, dividends, institutional ownership, risk and analyst recommendations.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Ionis Pharmaceuticals and ADC Therapeutics, as provided by MarketBeat.com.

Ionis Pharmaceuticals currently has a consensus target price of $57.9091, suggesting a potential upside of 41.14%. ADC Therapeutics has a consensus target price of $47.50, suggesting a potential upside of 104.65%. Given ADC Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe ADC Therapeutics is more favorable than Ionis Pharmaceuticals.

Earnings & Valuation

This table compares Ionis Pharmaceuticals and ADC Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Ionis Pharmaceuticals has higher revenue and earnings than ADC Therapeutics. ADC Therapeutics is trading at a lower price-to-earnings ratio than Ionis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Ionis Pharmaceuticals and ADC Therapeutics' net margins, return on equity and return on assets.

Institutional and Insider Ownership

84.1% of Ionis Pharmaceuticals shares are held by institutional investors. Comparatively, 40.9% of ADC Therapeutics shares are held by institutional investors. 2.4% of Ionis Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Ionis Pharmaceuticals beats ADC Therapeutics on 10 of the 13 factors compared between the two stocks.

ADC Therapeutics (NYSE:ADCT) and Sarepta Therapeutics (NASDAQ:SRPT) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, analyst recommendations, profitability, dividends and risk.

Profitability

This table compares ADC Therapeutics and Sarepta Therapeutics' net margins, return on equity and return on assets.

Insider & Institutional Ownership

40.9% of ADC Therapeutics shares are owned by institutional investors. Comparatively, 89.7% of Sarepta Therapeutics shares are owned by institutional investors. 5.9% of Sarepta Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares ADC Therapeutics and Sarepta Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

ADC Therapeutics has higher earnings, but lower revenue than Sarepta Therapeutics. ADC Therapeutics is trading at a lower price-to-earnings ratio than Sarepta Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current recommendations and price targets for ADC Therapeutics and Sarepta Therapeutics, as provided by MarketBeat.com.

ADC Therapeutics currently has a consensus target price of $47.50, suggesting a potential upside of 104.65%. Sarepta Therapeutics has a consensus target price of $150.4762, suggesting a potential upside of 110.40%. Given Sarepta Therapeutics' higher possible upside, analysts clearly believe Sarepta Therapeutics is more favorable than ADC Therapeutics.

Summary

ADC Therapeutics beats Sarepta Therapeutics on 7 of the 13 factors compared between the two stocks.

ADC Therapeutics (NYSE:ADCT) and Allakos (NASDAQ:ALLK) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, valuation, analyst recommendations, earnings, profitability and institutional ownership.

Profitability

This table compares ADC Therapeutics and Allakos' net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of recent ratings for ADC Therapeutics and Allakos, as provided by MarketBeat.com.

ADC Therapeutics currently has a consensus target price of $47.50, suggesting a potential upside of 104.65%. Allakos has a consensus target price of $181.50, suggesting a potential upside of 72.32%. Given ADC Therapeutics' higher probable upside, research analysts clearly believe ADC Therapeutics is more favorable than Allakos.

Valuation & Earnings

This table compares ADC Therapeutics and Allakos' revenue, earnings per share and valuation.

Allakos has lower revenue, but higher earnings than ADC Therapeutics. Allakos is trading at a lower price-to-earnings ratio than ADC Therapeutics, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

40.9% of ADC Therapeutics shares are held by institutional investors. Comparatively, 65.4% of Allakos shares are held by institutional investors. 44.8% of Allakos shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Blueprint Medicines (NASDAQ:BPMC) and ADC Therapeutics (NYSE:ADCT) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, profitability, institutional ownership, risk, analyst recommendations, earnings and valuation.

Profitability

This table compares Blueprint Medicines and ADC Therapeutics' net margins, return on equity and return on assets.

Institutional & Insider Ownership

40.9% of ADC Therapeutics shares are held by institutional investors. 3.8% of Blueprint Medicines shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Blueprint Medicines and ADC Therapeutics' gross revenue, earnings per share (EPS) and valuation.

ADC Therapeutics has lower revenue, but higher earnings than Blueprint Medicines. Blueprint Medicines is trading at a lower price-to-earnings ratio than ADC Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings for Blueprint Medicines and ADC Therapeutics, as provided by MarketBeat.com.

Blueprint Medicines presently has a consensus target price of $112.40, indicating a potential upside of 17.14%. ADC Therapeutics has a consensus target price of $47.50, indicating a potential upside of 104.65%. Given ADC Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe ADC Therapeutics is more favorable than Blueprint Medicines.

Summary

Blueprint Medicines beats ADC Therapeutics on 8 of the 14 factors compared between the two stocks.

ADC Therapeutics (NYSE:ADCT) and Perrigo (NYSE:PRGO) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, valuation, profitability, dividends, risk and analyst recommendations.

Institutional & Insider Ownership

40.9% of ADC Therapeutics shares are held by institutional investors. Comparatively, 82.7% of Perrigo shares are held by institutional investors. 0.3% of Perrigo shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares ADC Therapeutics and Perrigo's gross revenue, earnings per share and valuation.

Perrigo has higher revenue and earnings than ADC Therapeutics. ADC Therapeutics is trading at a lower price-to-earnings ratio than Perrigo, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for ADC Therapeutics and Perrigo, as provided by MarketBeat.com.

ADC Therapeutics presently has a consensus price target of $47.50, indicating a potential upside of 104.65%. Perrigo has a consensus price target of $52.00, indicating a potential upside of 25.36%. Given ADC Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe ADC Therapeutics is more favorable than Perrigo.

Profitability

This table compares ADC Therapeutics and Perrigo's net margins, return on equity and return on assets.

Summary

Perrigo beats ADC Therapeutics on 7 of the 13 factors compared between the two stocks.